Vlad Badescu
Internal Medicine · Largo, FLNPI 1699761973
Payments from drug & device makers
Across 567 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boehringer Ingelheim$538
- AstraZeneca$534
- Nestle Healthcare Nutrition Inc.$518
- GSK$407
- Pfizer$401
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,957100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,986 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $128,480 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $82,730 |
| MyrbetriqMirabegron | 47 | $47,347 |
| XareltoRivaroxaban | 16 | $14,394 |
| Pregabalin | 86 | $11,029 |
| Celecoxib | 45 | $8,933 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $8,334 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,765 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $5,874 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $5,750 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 30 | $4,374 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,104 |
| Duloxetine Hcl | 86 | $3,500 |
| Gabapentin | 182 | $3,273 |
| Methylprednisolone | 335 | $3,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $401 | $128,480119 claims |
| GSKTrelegy Ellipta | $407 | $82,73087 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $47,34747 claims |
| Johnson & JohnsonXarelto | $297 | $14,39416 claims |
| AstraZenecaSymbicort | $534 | $8,33420 claims |
| Boehringer IngelheimSpiriva Respimat | $538 | $7,76513 claims |
| Sanofi-aventis U.S. LLCLantus | $111 | $1,16613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Largo
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.